ARCHIVES

Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

Senate Approves 15% Increase For NIH; House Passes 5.6% Raise, But Favors More.

July 7, 2000

ASCO President Swain: “Shattering Impact on Cancer Enterprise”

February 15, 2013

In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs

November 27, 1998

Gallo Publishes Study to Resolve controversy Over HIV Discovery

March 15, 1991

Prognostic Factors Don’t Explain Better Prostate Cancer Survival In Most Asian Men

August 31, 2007

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

September 8, 2006